Ovarian cancer is the leading cause of gynecological cancer death. The first aim of our study was to evaluate if HE4 broadens the possibilities in ovarian cancer diagnostics.
The second aim was to evaluate the benefits of each biomarker of our panel. We compared the results of following tumor markers: CA 125, HE4, CA 19-9, CEA, TK, TPS, MonoTotal.
The total number of females in our study was 266.